Tudor Investment Corp ET AL Has $2.84 Million Position in BioLife Solutions, Inc. $BLFS

Tudor Investment Corp ET AL boosted its holdings in BioLife Solutions, Inc. (NASDAQ:BLFS) by 85.2% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 111,356 shares of the medical equipment provider’s stock after acquiring an additional 51,217 shares during the period. Tudor Investment Corp ET AL owned 0.23% of BioLife Solutions worth $2,841,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also added to or reduced their stakes in BLFS. Qube Research & Technologies Ltd increased its holdings in shares of BioLife Solutions by 2,399.5% in the second quarter. Qube Research & Technologies Ltd now owns 248,474 shares of the medical equipment provider’s stock valued at $5,352,000 after purchasing an additional 238,533 shares during the last quarter. Summit Creek Advisors LLC acquired a new stake in shares of BioLife Solutions during the 3rd quarter worth about $4,905,000. Ameriprise Financial Inc. boosted its holdings in shares of BioLife Solutions by 11.3% during the 2nd quarter. Ameriprise Financial Inc. now owns 1,080,371 shares of the medical equipment provider’s stock worth $23,271,000 after buying an additional 109,959 shares during the period. Deerfield Management Company L.P. boosted its holdings in shares of BioLife Solutions by 713.4% during the 3rd quarter. Deerfield Management Company L.P. now owns 111,195 shares of the medical equipment provider’s stock worth $2,837,000 after buying an additional 97,525 shares during the period. Finally, Bank of America Corp DE grew its stake in BioLife Solutions by 16.9% in the 2nd quarter. Bank of America Corp DE now owns 671,731 shares of the medical equipment provider’s stock valued at $14,469,000 after buying an additional 97,354 shares during the last quarter. Institutional investors and hedge funds own 93.24% of the company’s stock.

Wall Street Analyst Weigh In

BLFS has been the topic of several research analyst reports. Wall Street Zen raised shares of BioLife Solutions from a “hold” rating to a “buy” rating in a report on Saturday, February 28th. Northland Securities set a $34.00 target price on BioLife Solutions in a research report on Monday, January 5th. UBS Group reiterated a “buy” rating on shares of BioLife Solutions in a research note on Monday, December 29th. Zacks Research raised BioLife Solutions from a “hold” rating to a “strong-buy” rating in a report on Friday, January 23rd. Finally, HC Wainwright restated a “buy” rating and issued a $32.00 price target on shares of BioLife Solutions in a research note on Monday, December 29th. One investment analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $32.00.

Insider Buying and Selling

In related news, CFO Troy Wichterman sold 990 shares of the business’s stock in a transaction that occurred on Tuesday, January 6th. The stock was sold at an average price of $25.59, for a total value of $25,334.10. Following the completion of the sale, the chief financial officer directly owned 150,746 shares in the company, valued at approximately $3,857,590.14. The trade was a 0.65% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, insider Karen A. Foster sold 96,923 shares of the stock in a transaction that occurred on Thursday, March 5th. The stock was sold at an average price of $20.15, for a total value of $1,952,998.45. Following the sale, the insider directly owned 113,742 shares in the company, valued at $2,291,901.30. This represents a 46.01% decrease in their position. The SEC filing for this sale provides additional information. Over the last quarter, insiders sold 101,956 shares of company stock valued at $2,068,241. 2.20% of the stock is owned by company insiders.

BioLife Solutions Stock Down 5.4%

NASDAQ BLFS opened at $18.59 on Friday. The company has a market capitalization of $897.90 million, a P/E ratio of -168.98 and a beta of 1.90. BioLife Solutions, Inc. has a 12-month low of $17.86 and a 12-month high of $29.62. The firm has a 50-day moving average price of $21.71 and a two-hundred day moving average price of $24.41.

BioLife Solutions Company Profile

BioLife Solutions (NASDAQ:BLFS) specializes in biopreservation and cold chain workflow solutions for cell and gene therapies, regenerative medicine and other advanced biologics. The company develops and markets proprietary cryopreservation media and technology platforms designed to maintain cell viability and functionality during processing, storage and transport. BioLife’s product portfolio addresses critical steps in the manufacturing and distribution of cell-based products, helping life science researchers and biopharmaceutical manufacturers protect and preserve living cells.

The company’s flagship offerings include CryoStor, a family of serum-free cryopreservation media; HypoThermosol, a hypothermic storage solution for short-term cell and tissue preservation; and the ThawSTAR system, an automated cell thawing instrument that delivers controlled and reproducible warming of frozen cell therapies.